gsk glp 1 GLP-1 Support Homepage Pharma Pulse: The Oral GLP-1
Description
Mollan SP, Hoffmann J, Sinclair AJ
Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis
Phenomenex #chromatography #GLP1s #Peptides The Oral GLP1 Era Has Arrived And chromatographers are about to be very busy Sean Orlowicz, Pharmaceutical Market Development Manager - Phenomenex, dives into how oral GLP-1 therapies are reshaping the pharmaceutical landscapefrom improved patient convenience to new analytical and development challenges for peptide drugs
A longitudinal study further demonstrated that type 2 diabetes in older community-dwelling individuals is associated with a decline in verbal memory and fluency over approximately 5 years ( The effects of diabetes on brain atrophy may begin as early as midlife
Deadlines are set: state-licensed pharmacies stopped tirzepatide by February 18, 2025, and must halt GLP-1s by April 22, 2025
Ongoing care includes periodic check-ins with clinicians to monitor response and adjust dosing
